ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones
Source: SeekingAlpha
2026-01-12 09:27:53 ET
More on ORIC Pharmaceuticals
- ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript
- ORIC Pharmaceuticals GAAP EPS of -$0.33 beats by $0.08
- Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals
- Historical earnings data for ORIC Pharmaceuticals
- Financial information for ORIC Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones
Oric Pharmaceuticals Inc.
NASDAQ: ORIC
ORIC Trading
-2.04% G/L:
$12.01 Last:
396,960 Volume:
$12.48 Open:
ORIC Latest News
ORIC Stock Data
$1,023,561,322
83,384,701
0.22%
39
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
